drugset
drugset / Trial / NCT06900543

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

NCT06900543 ↗

Phase 3 Active not recruiting 108 enrolled Chengdu New Radiomedicine Technology Co. LTD.
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of NRT6003 Injection compared to cTACE in patients with unresectable HCC.

Timeline

Start
2025-04-15
Primary completion
2027-10
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject NRT6003 Injection Unknown — Other

Indications

hepatocellular carcinoma